Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C.

J Clin Endocrinol Metab. 1997 Jun;82(6):1661-7.

PMID:
9177359
2.

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.

J Clin Endocrinol Metab. 2005 Mar;90(3):1502-10. Epub 2004 Nov 30.

PMID:
15572415
3.

Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.

Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.

J Urol. 2011 Sep;186(3):1005-11. doi: 10.1016/j.juro.2011.04.065. Epub 2011 Jul 23.

PMID:
21788049
4.

Testosterone supplementation therapy for older men: potential benefits and risks.

Gruenewald DA, Matsumoto AM.

J Am Geriatr Soc. 2003 Jan;51(1):101-15; discussion 115. Review.

PMID:
12534854
5.

Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.

Raynaud JP, Gardette J, Rollet J, Legros JJ.

BJU Int. 2013 May;111(6):880-90. doi: 10.1111/j.1464-410X.2012.11514.x. Epub 2013 Jan 7.

6.
7.

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.

Clin Endocrinol (Oxf). 1997 Dec;47(6):727-37.

PMID:
9497881
8.

Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.

Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.

J Sex Med. 2014 Nov;11(11):2818-25. doi: 10.1111/jsm.12657. Epub 2014 Aug 18.

PMID:
25131184
9.

Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.

Hajjar RR, Kaiser FE, Morley JE.

J Clin Endocrinol Metab. 1997 Nov;82(11):3793-6.

PMID:
9360543
10.

Effects of testosterone replacement in hypogonadal men.

Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL.

J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7.

PMID:
10946864
11.

Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.

Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C.

J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80.

PMID:
15001605
12.
13.

Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.

Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.

Int J Impot Res. 2008 Nov-Dec;20(6):561-5. doi: 10.1038/ijir.2008.40. Epub 2008 Oct 9.

PMID:
18843272
14.

Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.

Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD.

J Androl. 2002 Nov-Dec;23(6):922-6.

15.

Testosterone supplementation does not worsen lower urinary tract symptoms.

Pearl JA, Berhanu D, Fran├žois N, Masson P, Zargaroff S, Cashy J, McVary KT.

J Urol. 2013 Nov;190(5):1828-33. doi: 10.1016/j.juro.2013.05.111. Epub 2013 Jun 11.

PMID:
23764078
16.

Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections.

Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C.

J Androl. 2006 Mar-Apr;27(2):165-75. Epub 2005 Nov 8. Erratum in: J Androl. 2006 May-Jun;27(3):480.

17.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.

18.

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).

Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM.

Clin Interv Aging. 2012;7:321-30. doi: 10.2147/CIA.S32036. Epub 2012 Aug 24.

19.

Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.

Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ.

Clin Endocrinol (Oxf). 2009 Jan;70(1):116-23. doi: 10.1111/j.1365-2265.2008.03327.x.

PMID:
18616708
20.

Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels.

Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM.

J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M321-5.

PMID:
11983727

Supplemental Content

Support Center